Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0HEDAZ
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
SC16.49-DL3
|
|||||
| Synonyms |
SC16.49 DL3; SC16.49DL3
Click to Show/Hide
|
|||||
| Organization |
AbbVie, Inc.
|
|||||
| Drug Status |
Investigative
|
|||||
| Indication |
In total 1 Indication(s)
Small cell lung cancer [ICD11:2C25]
Investigative
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Structure |
|
|||||
| Antibody Name |
SC16.49
|
Antibody Info | ||||
| Antigen Name |
Delta-like protein 3 (DLL3)
|
Antigen Info | ||||
| Payload Name |
SG2000 derivative PBD 3
|
Payload Info | ||||
| Therapeutic Target |
Human Deoxyribonucleic acid (hDNA)
|
Target Info | ||||
| Linker Name |
Mal-PEG8-Val-Ala
|
Linker Info | ||||
| Conjugate Type |
Random conjugation through reduced inter-chain cysteines.
|
|||||
| Combination Type |
AbbVie's DL3
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.